Advertisement
If you have a new account but are having problems posting or verifying your account, please email us on hello@boards.ie for help. Thanks :)
Hello all! Please ensure that you are posting a new thread or question in the appropriate forum. The Feedback forum is overwhelmed with questions that are having to be moved elsewhere. If you need help to verify your account contact hello@boards.ie
Hi there,
There is an issue with role permissions that is being worked on at the moment.
If you are having trouble with access or permissions on regional forums please post here to get access: https://www.boards.ie/discussion/2058365403/you-do-not-have-permission-for-that#latest

Elan?

  • 23-10-2009 1:13pm
    #1
    PcAngel
    Registered Users, Registered Users 2 Posts: 285 ✭✭


    could somebody please explain what is happening with Elan and should I hold on or sell. Down 28% since purchase!:eek:


Comments

  • #2
    Trading4Fun
    Closed Accounts Posts: 31 ✭Trading4Fun


    PcAngel wrote: »
    could somebody please explain what is happening with Elan and should I hold on or sell. Down 28% since purchase!:eek:

    Here is the news today:

    EMEA to review benefits and risks of Tysabri
    The Committee started a review of the benefits and risks of Tysabri, in view of reports of 23 cases of progressive multifocal leukoencephalopathy worldwide since Tysabri has been on the market. This review is initiated to discuss any additional measures necessary to ensure the safe use of Tysabri and how to balance the risks to the patients against the benefits of the treatment. Tysabri is indicated for patients suffering from highly active relapsing remitting multiple sclerosis with high disease activity despite treatment with a beta-interferon and for patients with rapidly evolving severe relapsing-remitting multiple sclerosis. Tysabri is co-marketed by Elan (ELN) and partner Biogen Idec (BIIB).


  • #3
    Trading4Fun
    Closed Accounts Posts: 31 ✭Trading4Fun


    Analyst update:

    Leerink expects Biogen shares to trade lower this morning after 23 total PML cases were reported in the EMEA's update. Leerink points out this implies 10-12 new PML cases since Biogen's last update. The firm is not overly alarmed but is looking for more details.


  • #4
    Comordha
    Closed Accounts Posts: 562 ✭✭✭Comordha


    I think if you are in it is all or nothing now. I am considering buying more.


  • #5
    PcAngel
    Registered Users, Registered Users 2 Posts: 285 ✭✭PcAngel


    Thanks for all the help. I'll hold tough so! What about Irish Life and P - should I cash in this evening - 15% up?


Advertisement